A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma

This is a prospective, 2-arm (with an additional exploratory arm), open-label, multicenter study looking at the response rate of patients receiving selinexor (KPT-330), in combination with carfilzomib, daratumumab or pomalidomide. Multiple Myeloma patients with documented disease progression or refractory disease while on current treatment with any carfilzomib-containing regimen (arm 1), any pomalidomide-containing regimen (arm 2) or any daratumumab-containing regimen (exploratory arm) will be included in the study. Patients will be assigned to the respective groups according to their current

Trial Details

NCT ID
NCT04661137
Phase
PHASE2
Sponsor
Hackensack Meridian Health
Status
RECRUITING
Cancer Type
Multiple Myeloma
Interventions
  • Selinexor 60 MG
  • Selinexor 80 MG
  • Selinexor 100 MG
  • Carfilzomib
  • Pomalidomide
  • Daratumumab
Locations (sample)
  • Washington D.C., District of Columbia, United States|38.89511,-77.03637
  • Hackensack, New Jersey, United States|40.88593,-74.04347

Key Eligibility Criteria

  • Age ≥18 years at time of informed consent.
  • Histologically confirmed MM and evidence of disease progression while on one of the below MM regimens:
  • Arm 1: Refractory to or disease progression while on a carfilzomib-containing regimen
  • Arm 2: Refractory to or disease progression while on a pomalidomide-containing regimen

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Multiple Myeloma Trials on Trialify →